MDCX News & Events

New to The Street has signed a six-part media series with Medicus Pharma. The comprehensive series is designed to elevate Medicus' visibility with institutional investors, analysts, and the broader healthcare and life sciences community through a multi-channel media and investor engagement strategy. The engagement will spotlight Medicus Pharma's clinical progress, management vision, and long-term growth opportunities, delivering consistent, high-quality exposure over the course of the engagement.

Medicus Pharma announces that it has received "study may proceed" clearance from the U.S. Food and Drug Administration, FDA, to initiate its Phase 2b dose-optimization study of Teverelix, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer, APC.

Medicus Pharma announces that its subsidiary, Antev, has entered into Amendment No. 3 to its license agreement with LifeArc relating to Teverelix. Under the amended agreement, the royalty rate payable on worldwide net sales of Teverelix has been reduced from ~4% to 2%, with the royalty term clarified on a country-by-country basis in line with standard industry practice. The amendment does not alter the scope of the license, the underlying intellectual property, or the respective development responsibilities of the parties, and all other terms of the original agreement remain in full force and effect.

Medicus Pharma announces that detailed clinical data on Teverelix, its long-acting gonadotropin-releasing hormone antagonist, have been accepted for e-Poster presentation at the American Association of Clinical Endocrinology, AACE, Annual Meeting 2026, to be held April 22-24 in Las Vegas, Nevada. Phase 1 Results: Rapid suppression of LH and FSH within 24 hours of dosing; Dose-dependent and reversible estradiol suppression, with multiple participants achieving levels within the clinically relevant Barbieri window, a range associated with symptom control while mitigating bone loss risk; Sustained pharmacodynamic activity, with hormone suppression lasting up to two to three weeks following a single injection at higher doses; Stable bone turnover markers, suggesting no evidence of short-term bone loss; Favorable safety profile, with no drug-related serious adverse events and only mild-to-moderate treatment-emergent adverse events reported. Additionally, the SkinJect Phase 2 Program on Track for Near-Term Data Readout